DEVELOPMENT AND CHARACTERIZATION OF NON-IONIC SURFACTANT VESICLES FOR OPHTHALMIC DRUG DELIVERY OF DICLOFENAC POTASSIUM by Rastogi, Bhavya et al.
Rastogi et al                  JDDT; Special Issue1: "Drug Delivery using Nanomedicine & Nanotechnology"              1 
© 2011-14, JDDT. All Rights Reserved                                                ISSN: 2250-1177                                                CODEN (USA): JDDTAO 
Available online on 25.06.2014 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open access to Pharmaceutical and Medical research 
© 2014, publisher and licensee JDDT, This is an Open Access article which permits unrestricted noncommercial use, provided the original 
work is properly cited 
 
RESEARCH ARTICLE 
DEVELOPMENT AND CHARACTERIZATION OF NON-IONIC SURFACTANT 
VESICLES FOR OPHTHALMIC DRUG DELIVERY OF DICLOFENAC POTASSIUM 
Rastogi Bhavya 
*
, Nagaich Upendra
 1
, Jain D.A.
2
 
Department of Pharmaceutics, Sun Institute of Pharmaceutical Education & Research, Lahar, 477445, M.P., India 
1Department of Pharmaceutics, Amity School of Pharmacy, Amity University, Noida, U.P., India 
2Department of Pharmaceutics, Institute of Pharmaceutical Sciences and Research Centre, Bhagwant University, 
Ajmer, Rajasthan, India 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The treatment of infections and inflammatory conditions 
of eyes caused by obligate and intracellular 
microorganism is difficult because most of the antibiotics 
have poor intracellular diffusion, low ocular contact 
time, poor corneal penetration and solubility limitation. 
The need for drug delivery system with greater 
intracellular efficacy led to the development of 
Diclofenac potassium Non ionic surfactant vesicles with 
good sustained release profile, increased ocular contact 
time, good entrapment efficiency, improved corneal 
penetration and bioavailability characteristics.  
Niosomes are essentially non-ionic surfactant based 
multi lamellar vesicles in which an aqueous solution of 
solute is entirely enclosed by a membrane resulted from 
the organization of surfactant macro molecule as 
bilayer1. The present formulation is hydrated mixture of 
cholesterol and Span 60. They consist of pharmaceutical 
ingredient and serves as drug carrier2. They provide 
controlled ocular delivery by preventing the metabolism 
of the drug from the enzymes present at the tear/corneal 
epithelial surface3. These drug carriers, when 
administered intravenously are rapidly taken up by cells 
of corneal surface; inhibit both, leukocyte migration and 
the enzyme cylooxygenase. Therefore the entrapment of 
drug within Niosomes has been proposed for the 
treatment of infections and inflammatory conditions4. 
Moreover, Niosome preparations are chemically stable, 
precise in chemical composition, cheaper in cost, have 
low toxicity5 because of their non-ionic nature and 
independent of the pH. Diclofenac potassium has low 
bioavailability, low solubility and short half life that 
make it a candidate for controlled delivery. They can 
also widely accept as prophylaxis against cystoid’s 
macular edema. The aim of the present work is to 
formulate niosomal drug delivery system of Diclofenac 
potassium to be applied topically and to evaluate the in- 
vitro and In-vivo performance of the prepared niosome. 
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ABSTRACT 
Non-ionic surfactant vesicles was developed and characterized for ophthalmic drug delivery of Diclofenac potassium. The 
present research study is a promising approach to improve corneal penetration and bioavailability characteristics. Formulation 
also found to ensure a good entrapment efficiency and ocular bioavailability of drug in-vivo. Non-ionic surfactant vesicles 
containing Diclofenac potassium were prepared using surfactant and cholesterol in different ratio by Lipid film hydration 
technique. Niosomes were characterized For Entrapment efficiency, Particle size analysis, In-vitro drug release and In-vivo 
studies. The best formulation selected based on above parameters were subjected for sustained release study. Formulation  with 
low cholesterol content which shown 82.1% Entrapment efficiency, 70.01% sustained release over a period of 10 h followed a 
non-fickian profile with zero order release profile. Scanning electron micrograph indicated that Niosomes have a discrete 
spherical structure without aggregation. In-vivo study showed an availability of drug in aqueous humor for an extended time 
period even up to 8 hour and it showed a correlation with the release profile in-vitro. Non-ionic surfactant vesicles are 
considered the best as it showed good and high Entrapment efficiency and Vitro release with better bioavailability. The 
proposed method was found to be precise and selective for the development and characterization of Diclofenac potassium 
Niosomes. 
Key words: Diclofenac potassium, corneal penetration, sorbitan mono stearate, Entrapment efficiency, SEM, in vitro release 
study, HPLC. 
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MATERIALS AND METHODS 
Diclofenac potassium was obtained as a gift sample from 
Novartis limited, India. Cholesterol, Span 60, 
Chloroform and Methanol (L.R grade) were purchased 
from Loba chemie, Mumbai. All other chemicals used 
were of analytical grade. 
Preparation of Niosomes 
Diclofenac potassium Niosomes were prepared by lipid 
film hydration technique6. Span 60 and Cholesterol were 
weighed and dissolved in chloroform /methanol (2:1) in 
a 100 ml round bottom flask. A thin lipid film formed 
under reduced pressure in a rotary flash evaporator. The 
film then hydrated by 10 ml of phosphate buffer 7.4 at 
room with gentle shaking. The Niosome suspension 
further hydrated up to 24 Hrs at 2-80 C. The stabilized 
vesicles were used for further studies7. This phosphate 
buffer 7.4 was made with 2.38 gm of Di-sodium 
hydrogen phosphate, 0.19 gm of potassium di-hydrogen 
phosphate and 8.0 gm of sodium chloride and made up to 
1000 ml with distilled water8. The formed Niosomes 
were separated by fractional centrifugation. Various 
formulations containing different ratio of cholesterol and 
surfactants were appropriately labelled respectively as 
shown in the table 1. 
 
Table 1: Formulation table of Diclofenac Potassium Niosomes 
Formulation No. Ratio (µmol) 
(surfactant: cholesterol) 
Surfactant (mg) Cholesterol (mg) 
F 1 
F 2 
F 3 
F 4 
F 5 
F 6 
F 7 
F 8 
F 9 
F10 
F11 
200:200 
200:175 
200:150 
200:125 
200:115 
200:100 
200: 85 
200: 75 
150:200 
150:150 
150:125 
86 
86 
86 
86 
86 
86 
86 
86 
64.5 
64.5 
64.5 
77.32 
67.66 
57.9 
48.32 
44.45 
38.66 
32.8 
28.19 
77.32 
57.9 
48.32 
 
Characterization:  
The prepared Diclofenac potassium Niosomes were 
subjected to Entrapment efficiency determination, 
Particle size analysis, In-vitro release and In-vivo study. 
Entrapment Efficiency 
Niosome entrapped Diclofenac potassium was estimated 
by dialysis method9. The prepared Niosomes were placed 
in the dialysis bag 50 (pre-soaked for 24 hrs). Free 
Diclofenac potassium was dialyzed for 30 minutes each 
time in 100 ml of phosphate buffer saline pH 7.4. The 
dialysis of free Diclofenac always complete after 12-15 
changes, when no Diclofenac was detectable in the 
recipient solution. The dialyzed Diclofenac potassium 
determined by finding out the concentration of bulk of 
solution by UV spectrophotometer at 275 nm. The 
samples from the bulk of solution diluted ten times 
before going for absorbance measurement.  The free 
Diclofenac in the bulk of solution gives us the total 
amount of un-entrapped drug. Encapsulation efficiency is 
expressed as the percent of drug trapped.   
 Total drug -- Diffused drug  
 % Entrapment =                                                    X 100 
                                            Total drug         
 
Particle size analysis 
Particle size analysis was carried out using scanning 
electron microscopy. 
In vitro release study 
 In vitro release study of prepared Niosomes was carried 
out in dialysis bag method10. 0.2 mg equivalent of 0.1% 
of Niosomal suspension was taken in dialysis bag (Hi 
media) and the bag was placed in a beaker containing 
100 ml simulated tear fluid11 (pH7.4 phosphate buffer). 
The beaker was placed over magnetic stirrer and the 
temperature was maintained at 37+10C. 5 ml sample 
were withdrawn periodically and were replaced by fresh 
buffer. The sink condition was maintained throughout 
the experiment. The withdrawn samples were diluted 2 
times. The amount of drug release was determined 
spectrophoto-meterically at 280 nm keeping phosphate 
buffer pH 7.4 as blank. 
In-vivo study 
In-vivo study12-14 conducted in the animal model rabbit. 
Four healthy rabbits were used for the study. 3 drops of 
0.1 % niosomal suspension of Diclofenac potassium was 
instilled in the lower cul-de-sac of each eye. The upper 
eyelids were gently held closed for 10 seconds to 
maximize the corneal contact. At the 4th and 8th hour of 
post dose eyes were anesthetized using 4% Xylocaine 
solutions. Topically and aqueous humor The mixture was 
then centrifuged at 3000 rpm for 20 minutes and the 
supernatant obtained was analyzed for the presence of 
Diclofenac potassium by HPLC detector, by comparing 
with the retention time of a standard solution 
(50µg/ml)15. 
Qualitative estimation of Diclofenac potassium was done 
by HPLC. Filtered degassed mixture of Methanol and 
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Sodium acetate 0.1M (60:40) was used as mobile 
phase16. 
RESULTS AND DISCUSSION 
Diclofenac potassium Niosomes with same proportion of 
drug and varying proportions of Non ionic surfactant 
(Span-60) with Cholesterol, were prepared by lipid film 
hydration technique. Entrapment efficiency 
determination study suggests that higher entrapment 
efficiency from vesicle formed of span 60 is predictable 
because of its higher alkyl chain length. The entrapment 
efficiency is found to be higher with the formulation no. 
F6 (82.10) which has said to be the optimum cholesterol 
surfactant ratio to provide a high entrapment of 
Diclofenac potassium. The niosomal formulations having 
high surfactant concentration have the higher entrapment 
efficiency which may be due to the high fluidity of the 
vesicles. Very low cholesterol content too found to cause 
low entrapment efficiency, it may be because of leakage 
of the vesicles. It’s also observable that very high 
cholesterol content also has a lowering effect on drug 
entrapment to the vesicles. This could be due to the fact 
that cholesterol beyond a certain level starts disrupting 
the regular bi-layered structure leading to loss of drug 
entrapment.  
 
Figure 1: Entrapment efficiency of Diclofenac potassium 
Niosomes 
Entrapment efficiency of various formulations is shown 
in fig. 1. 
 
Figure 2: Scanning Electron Micrograph of Diclofenac 
potassium Niosomes 
The Scanning electron micrograph of Diclofenac 
potassium Non ionic surfactant vesicles is shown in fig. 
2. It indicated that Niosomes have a discrete spherical 
structure without aggregation. The particle size differed 
due to variation in the composition of the formulation. 
The shrinking of vesicles was observed under the study 
may be due to drying of vesicles under normal 
environment condition. The particle size differed due to 
variation in the composition of the formulation. In-vitro 
drug release profile has been described in figure is shown 
in fig. 3. The releases of the drug from various 
formulations are clearly the attributes of the varying 
cholesterol and surfactant ratios.                                                    
     
 
Fig. 3: Comparative Assessment of In-vitro drug release profile of the Formulations 
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Table 2: Regression analysis of models for all formulations 
Formulations Zero order Higuchi’s Peppa’s 
Slope Correlation Slope Correlation Slope Correlation 
F1 5.6826 0.9956 18.2973 0.9542 1.2040 0.8691 
F2 5.3567 0.9952 17.7922 0.9511 1.2074 0.9823 
F3 5.7173 0.9974 18.8995 0.9487 1.2704 0.9039 
F4 6.0543 0.9970 20.2571 0.9598 1.2267 0.8696 
F5 6.2483 0.9989 28.9314 0.9938 1.0000 0.9040 
F6 6.5599 0.9967 21.9748 0.9607 1.2358 0.8613 
F7 6.9329 0.9943 23.4715 0.9797 1.2392 0.8448 
F8 7.2887 0.9929 25.0848 0.9832 1.2386 0.8341 
F9 5.0068 0.9945 16.6064 0.9491 1.1898 0.8846 
F10 5.2206 0.9947 17.5716 0.9633 1.1661 0.8589 
F11 5.8270 0.9967 19.6144 0.9653 1.2107 0.8652 
 
All the 11 batches of Diclofenac potassium Niosomes 
exhibited sustained release for about period of 10 hr.  
Most of the formulations were found to show a linear 
release and the formulations were found to provide 
approximately 60% release within a period of 10 hours. 
The formulations which have high cholesterol ratio (F9, 
F10) were found to sustain the drug release.  Cholesterol 
has a property of abolish the gel to liquid transition of 
Niosomes, this found to prevent the leakage of drug from 
the niosomal formulation.   The three optimized 
formulations F4, F5, and F6 were found to give a release 
of 64.04%, 64.17% and 70.01% respectively over a 
period of 10 hrs, the higher release from the formulation 
F6 may be because of its low cholesterol content. 
Formulations F9 and F10 has the lowest release over 10 
hours they provide a release of 52.47% and 56.43% 
respectively, which has the highest cholesterol content. 
At the end of 10hr formulation F1 to F11 released about 
59.42%, 57.38%, 57.45%, 64.04%, 64.17%, 70.01%, 
72.07%, 75.94%, 52.47%, 56.43% and 61.31% 
respectively. In order to find out the mechanism of drug 
release, the in-vitro drug release data was graphically 
treated according to Higuchi’s equation and the graphical 
fit for the in-vitro data was used to conclude the 
mechanism of the drug release involved in the delivery 
system. Correlation value of Higuchi’s plot revealed that 
the mechanism of drug release is diffusion. The 
correlation value of zero order plots and correlation 
value of Higuchi’s plots with peppa’s plots presented in 
table no. 2. The best formulation selected based on 
Physico-chemical parameters were subjected for 
sustained release study is F6. Separate graphs for F6 listed 
below. In vivo study conducted to investigate the ocular 
availability of drug for a prolonged action after a single 
dose. The study carried out by comparing the retention 
time of the standard drug solution to that of the aqueous 
humors extracted sample. The retention time obtained 
here for the standard is 4.52 minutes, for the samples at 
4th and 8th hour are 4.780 and 4.660 minutes respectively. 
This matching retention time of three samples shows the 
presence of drug Diclofenac potassium in the aqueous 
humor sample even after 4th and 8th hour of 
administration. Thus drug is available in detectable 
quantities even after 8th hour of administration.  This 
may be because of possible retention of drug in the 
aqueous humor due to high corneal contact time and 
permeability provided by the vesicular system. In-vivo 
study is shown in fig. 4, 5 and 6 respectively.
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Figure 4: HPLC Peak for the standard solution 
 
 
Figure 5: HPLC Peak for the sample at 4th h 
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Figure 6: HPLC Peak for the sample at 8th h 
CONCLUSION 
The method of preparation of Niosomes of Diclofenac 
potassium was found to be simple and reproducible. The 
slow and constant release of Diclofenac potassium from 
Niosomes maintains constant drug plasma concentration 
thereby increasing therapeutic efficacy and reducing the 
development of resistance. This study shows that Non-
ionic surfactant Niosomes could be a useful carrier for 
Diclofenac potassium. 
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